Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023

Rhea-AI Summary

Omeros Corporation (NASDAQ: OMER) is set to release its fourth quarter and year-end financial results for the period ending December 31, 2022, on March 13, 2023, after the market closes. Following the release, Omeros management will host a conference call at 4:30 p.m. ET to discuss the results and recent developments. Omeros specializes in developing therapeutics for immunologic disorders, with its lead candidate, narsoplimab, currently pending FDA approval for treating TA-TMA. The company is also pursuing multiple late-stage clinical programs for various complement-mediated disorders, including IgA nephropathy and COVID-19.

Positive

• Pending FDA approval for narsoplimab as a treatment for TA-TMA.
• Multiple late-stage clinical development programs for complement-mediated disorders.

Negative

• None.

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Conference Call Details

To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the “Call Me” option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN.

The live or subsequently archived webcast of the event can be accessed at this link.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and one or more related indications. For more information about Omeros and its programs, visit www.omeros.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005584/en/

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

IR@omeros.com

Source: Omeros Corporation

FAQ

When will Omeros Corporation announce its fourth quarter and year-end financial results?

Omeros Corporation will announce its financial results on March 13, 2023, after the market closes.

What is the significance of narsoplimab for Omeros Corporation?

Narsoplimab is Omeros' lead candidate pending FDA approval for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

What time will the conference call for Omeros Corporation's financial results take place?

The conference call will take place at 4:30 p.m. Eastern Time on March 13, 2023.

What disorders is Omeros Corporation targeting with its therapeutics?

Omeros is targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders.